{
  "format": "listen-step-protocol@1",
  "kind": "module",
  "name": "Doxil-type PEGylated liposomal doxorubicin",
  "tags": [
    "Liposome",
    "Literature recipe"
  ],
  "steps": [],
  "labItems": [
    {
      "id": "component-doxil-pegylated-liposomal-doxorubicin",
      "kind": "recipe",
      "afterStep": 0,
      "snapshot": {
        "id": "literature-doxil-pegylated-liposomal-doxorubicin",
        "kind": "recipe",
        "name": "Doxil-type PEGylated liposomal doxorubicin",
        "category": "Liposome",
        "tags": [
          "Liposome",
          "Literature recipe"
        ],
        "steps": [],
        "materials": [
          {
            "name": "HSPC",
            "detail": "Hydrogenated soy phosphatidylcholine; 56.4 mol%"
          },
          {
            "name": "Cholesterol",
            "detail": "38.3 mol%"
          },
          {
            "name": "DSPE-PEG2000",
            "detail": "5.3 mol%"
          },
          {
            "name": "Doxorubicin",
            "detail": "2 mg/mL total in the research PLDs"
          },
          {
            "name": "Ammonium sulfate",
            "detail": "250 mM research preparation; establish and remove the external gradient as described in the source"
          }
        ],
        "tables": [
          {
            "id": "membrane",
            "name": "PEGylated lipid membrane",
            "header": [
              "Component",
              "Molar percentage",
              "Role"
            ],
            "rows": [
              [
                "HSPC",
                "56.4 mol%",
                "High-transition-temperature membrane lipid"
              ],
              [
                "Cholesterol",
                "38.3 mol%",
                "Membrane composition"
              ],
              [
                "DSPE-PEG2000",
                "5.3 mol%",
                "PEGylated lipopolymer"
              ]
            ]
          },
          {
            "id": "research-pld",
            "name": "Research PLD context",
            "header": [
              "Parameter",
              "Value",
              "Source scope"
            ],
            "rows": [
              [
                "Total lipid",
                "16 mg/mL",
                "Wei et al. research PLDs"
              ],
              [
                "Total doxorubicin",
                "2 mg/mL",
                "Wei et al. research PLDs"
              ],
              [
                "Ammonium sulfate",
                "250 mM",
                "Research preparation and gradient condition"
              ],
              [
                "Diameter",
                "75–85 nm; PDI 0.05–0.07",
                "Research PLDs, not a release specification"
              ]
            ]
          }
        ],
        "tableChoices": {},
        "author": "Listen Step",
        "origin": {
          "type": "curated-literature",
          "url": "https://doi.org/10.1016/j.jconrel.2012.03.020",
          "reviewedAt": "2026-11-09"
        },
        "source": {
          "citation": "Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release 160, 117–134 (2012).",
          "doi": "10.1016/j.jconrel.2012.03.020",
          "url": "https://doi.org/10.1016/j.jconrel.2012.03.020",
          "locator": "Composition and preparation of Doxil"
        },
        "related_sources": [
          {
            "citation": "Wei X et al. Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance. ACS Omega 3, 2508–2517 (2018).",
            "doi": "10.1021/acsomega.7b01235",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6044617/",
            "locator": "Methods, PLD composition and preparation; Table 1 and Figure 2"
          },
          {
            "citation": "Bulbake U et al. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9, 12 (2017).",
            "doi": "10.3390/pharmaceutics9020012",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5489929/",
            "locator": "Table 1 and Section 3.1.1, Doxil"
          }
        ],
        "review": {
          "status": "source-values-checked",
          "reviewedAt": "2026-11-09",
          "scope": "Literature composition only, not a clinical product manufacturing or administration protocol. The 250 mM ammonium sulfate and 75–85 nm values come from Wei et al.'s research PLDs, not instructions for producing a clinical batch."
        },
        "createdAt": 1794182400000,
        "updatedAt": 1794182400000
      }
    }
  ],
  "materials": [
    {
      "name": "HSPC",
      "detail": "Hydrogenated soy phosphatidylcholine; 56.4 mol%"
    },
    {
      "name": "Cholesterol",
      "detail": "38.3 mol%"
    },
    {
      "name": "DSPE-PEG2000",
      "detail": "5.3 mol%"
    },
    {
      "name": "Doxorubicin",
      "detail": "2 mg/mL total in the research PLDs"
    },
    {
      "name": "Ammonium sulfate",
      "detail": "250 mM research preparation; establish and remove the external gradient as described in the source"
    }
  ],
  "source": {
    "citation": "Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release 160, 117–134 (2012).",
    "doi": "10.1016/j.jconrel.2012.03.020",
    "url": "https://doi.org/10.1016/j.jconrel.2012.03.020",
    "locator": "Composition and preparation of Doxil"
  },
  "review": {
    "status": "source-values-checked",
    "reviewedAt": "2026-11-09"
  }
}
